Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05366855 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
A Phase 3 study, sponsored by Vanda Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 42
- Enrollment target
NCT05366855 is a Phase 3 study that was terminated before completion, run by Vanda Pharmaceuticals. The registered enrollment target is 42 participants.
The verdict
NCT05366855, a Phase 3 study, was terminated before completion, sponsored by Vanda Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is a Phase 3, long term extension study to evaluate the safety and efficacy of imsidolimab compared with placebo in adult subjects with generalized pustular psoriasis (GPP).
Interventions
- OTHER Placebo
- OTHER Standard of Care (SOC)
- DRUG Double-blind 200 mg imsidolimab
- DRUG Open-label 200 mg imsidolimab
- DRUG Imsidolimab 750 mg IV/200 mg SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2022-04-21 |
| Est. Completion | 2024-07-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05366855
The ClinicalTrials.gov registry entry for NCT05366855 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT05366855 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05366855 about?
NCT05366855 is a clinical study titled "Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP". This is a Phase 3, long term extension study to evaluate the safety and efficacy of imsidolimab compared with placebo in adult subjects with generalized pustular psoriasis (GPP).
What is the current status of trial NCT05366855?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 42 participants. The study started on 2022-04-21. Estimated completion is 2024-07-12.
What interventions are being tested in trial NCT05366855?
The interventions under investigation include: Placebo (OTHER), Standard of Care (SOC) (OTHER), Double-blind 200 mg imsidolimab (DRUG), Open-label 200 mg imsidolimab (DRUG), Imsidolimab 750 mg IV/200 mg SC (DRUG).
Who is sponsoring clinical trial NCT05366855?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.